RESUMEN
The conjugation of cytotoxic drugs to monoclonal antibodies (mAbs) generates heterogeneous drug load distribution. Antibody-drug conjugates (ADC) are physically less stable as compared to their parent molecule due to modifications made in order to link drugs to the interchain sulfhydryl groups of monoclonal antibodies. The conjugation of small molecule drugs to mAbs alters the physicochemical properties of mAbs and also impacts their degradation profile. The use of appropriate analytical tools to monitor physical stability changes is necessary to identify key product quality attributes such as aggregation. This chapter discusses suitable stress conditions and the use of stability indicating analytical methods to detect degradation products.
Asunto(s)
Antineoplásicos Inmunológicos/química , Fenómenos Químicos , Inmunoconjugados/química , Anticuerpos Monoclonales/química , Antineoplásicos Inmunológicos/análisis , Rastreo Diferencial de Calorimetría , Estabilidad de Medicamentos , Humanos , Inmunoconjugados/análisis , TermodinámicaRESUMEN
The conjugation of hydrophobic cytotoxic agents such as monomethyl auristatin E (MMAE) to the interchain sulfhydryl groups of monoclonal antibodies (Mabs) through a protease-labile linker generates a heterogeneous drug load distribution. The conjugation process can generate high-drug-load species that can affect the physical stability of antibody-drug conjugates (ADCs). In this study, the mechanism of physical instability of ADCs was investigated by formulating the ADC pool as well as isolated drug load species in high and low ionic strength buffers to understand the effect of ionic strength on the stability of drug-conjugated Mabs. The results showed that the presence of high ionic strength buffer led to time-dependent aggregate and fragment formation of ADCs, predominantly ADCs with high-drug-load species under stress conditions. In addition, differential scanning calorimetry (DSC) results confirmed that there is a direct correlation between thermal unfolding and drug payload and that specific changes in the DSC thermogram profiles can be assigned to modifications by MMAE.
Asunto(s)
Anticuerpos Monoclonales/química , Inmunoconjugados/química , Oligopéptidos/química , Animales , Células CHO , Rastreo Diferencial de Calorimetría , Cricetulus , Estabilidad de Medicamentos , Humanos , Concentración Osmolar , Factores de TiempoRESUMEN
We investigated the photo-protective effect of sugar-based surfactants--hexyl glucoside and hexyl maltoside--against light-induced oxidation of a monoclonal antibody. Reactive oxygen species are generated in solutions in the presence of light; these reactive species readily oxidize amino acids such as tryptophan. Hexyl glucosides and hexyl maltosides scavenge these reactive species and protect tryptophan residues from light-induced oxidation in a concentration-dependent manner. As a result of the scavenging process, hydrogen peroxide is formed, especially at high (millimolar) concentrations of the alkyl glycoside surfactants. These results suggest that hexyl glucoside and hexyl maltoside have the potential to protect tryptophan residues against light-induced oxidation.
Asunto(s)
Glucósidos/química , Maltosa/química , Tensoactivos/química , Triptófano/química , Triptófano/efectos de la radiación , Aminoácidos/química , Cromatografía en Gel , Estabilidad de Medicamentos , Humanos , Peróxido de Hidrógeno/análisis , Hidrólisis , Inmunoglobulina G/química , Luz , Oxidación-Reducción , Oxígeno/química , Espectrometría de Fluorescencia , TripsinaRESUMEN
Rinderpest is an acute and highly contagious viral disease of ruminants, often resulting in greater than 90% mortality. We previously reported the development of first- and second-generation recombinant vaccinia virus vaccines which provide complete protection against rinderpest virus (RPV) and peste-des-petits ruminants virus (PPRV). These vaccines are safe even for immunodeficient mice and macaques with acquired immunodeficiency syndrome. We developed a third-generation recombinant vaccinia virus vaccine (v2RVFH) that expresses the fusion and haemagglutinin genes of RPV under strong synthetic vaccinia virus promoters. Cattle vaccinated intramuscularly with as little as 10(3) plaque-forming units (PFU) of v2RVFH were completely protected from rinderpest. Vaccinated animals did not develop pock lesions or transmit v2RVFH to contact animals. Cattle vaccinated with a standard dose of 10(8) PFU of v2RVFH developed long-term, sterilizing immunity against rinderpest. Thus, v2RVFH is safe, efficacious, heat stable, inexpensive, easily administered, and allows serological differentiation between vaccinated and infected animals. To aid in diagnosis and differentiation of vaccinated from infected animals, we developed indirect ELISAs (iELISAs) that use baculovirus-expressed RPV or PPRV nucleoprotein as coating antigens. A single larva contains enough viral antigen to test more than 10,000 serum samples, in duplicate. African scientists trained at the ILMB successfully transferred the iELISA kit technology to more than 30 countries in Africa, providing a model for technology transfer among developing countries. Vaccination with v2RVFH, in conjunction with the iELISA kits, greatly enhances the prospects for global eradication of rinderpest, as developing nations achieve independence in control efforts.
Asunto(s)
Juego de Reactivos para Diagnóstico/veterinaria , Peste Bovina/epidemiología , Peste Bovina/prevención & control , Vacunas Virales , África , Animales , Asia , Bovinos , Costos y Análisis de Costo , Países en Desarrollo , Ensayo de Inmunoadsorción Enzimática/métodos , Ensayo de Inmunoadsorción Enzimática/veterinaria , Vacunas Virales/economíaRESUMEN
The vaccinia virus (VV) B8R gene encodes a secreted protein with homology to the gamma interferon (IFN-gamma) receptor. In vitro, the B8R protein binds to and neutralizes the antiviral activity of several species of IFN-gamma, including human and rat IFN-gamma; it does not, however, bind significantly to murine IFN-gamma. Here we report on the construction and characterization of recombinant VVs (rVVs) lacking the B8R gene. While the deletion of this gene had no effect on virus replication in vitro, rVVs lacking the B8R gene were attenuated for mice. There was a significant decrease in weight loss and mortality in normal mice, and nude mice survived significantly longer than did controls inoculated with parental virus. This is a surprising result considering the minimal binding of the B8R protein to murine IFN-gamma and its failure to block the antiviral activity of this cytokine in vitro. Such reduction in virulence could not be determined in rats, since they are considerably more resistant to VV infection than are mice. Finally, deletion of the B8R gene had no detectable effects on humoral immune responses. Mice and rats vaccinated with the rVVs showed identical humoral responses to both homologous and heterologous genes expressed by VV. This study demonstrates that the deletion of the VV B8R gene leads to enhanced safety without a concomitant reduction in immunogenicity.
Asunto(s)
Vectores Genéticos , Receptores de Interferón/fisiología , Virus Vaccinia/patogenicidad , Animales , Femenino , Eliminación de Gen , Humanos , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Ratas , Ratas Endogámicas F344 , Receptores de Interferón/genética , Virus Vaccinia/genética , Virus Vaccinia/inmunología , Virulencia , Replicación Viral , Receptor de Interferón gammaRESUMEN
The only vaccines shown to be protective against intravenous challenge with virulent virus in the simian immunodeficiency virus (SIV)/macaque model are attenuated live SIVs. However, these vaccines have several disadvantages: 1) they persist indefinitely in vaccinated macaques; 2) they are pathogenic to neonatal macaques; and 3) they are lethal in some adult macaques. To enhance the safety and efficacy of these vaccines, we immunized macaques first with recombinant vaccines and then inoculated the animals with SIV(delta(nef)). In the first experiment, preimmunized macaques advanced to disease slower than controls after challenge with virulent SIV; five animals survived for 3 years without disease and only the vaccine virus (SIV(delta(nef)) could be isolated at this time. In the second experiment, preimmunized animals had lower virus loads and no disease compared to controls.
Asunto(s)
Linfocitos/inmunología , Vacunas contra el SIDAS/inmunología , Síndrome de Inmunodeficiencia Adquirida del Simio/inmunología , Virus de la Inmunodeficiencia de los Simios/inmunología , Vacunas Atenuadas/inmunología , Vacunas Sintéticas/inmunología , Animales , Formación de Anticuerpos , Modelos Animales de Enfermedad , Macaca mulatta , Provirus/genética , Provirus/inmunología , Vacunas contra el SIDAS/toxicidad , Seguridad , Vacunas Atenuadas/toxicidad , Carga ViralRESUMEN
Analysis of immune responses generated by live-attenuated simian immunodeficiency virus (SIV) strains may provide clues to the mechanisms of protective immunity induced by this approach. We examined SIV-specific T-helper responses in macaques immunized with the live-attenuated SIV strains SIVmac239deltanef and SIVmac239delta3. Optimization of the concentration and duration of antigenic stimulation resulted in the detection of relatively strong SIV-specific proliferative responses, with peak stimulation indices of up to 84. SIV-specific proliferative responses were mediated by CD4+ T cells and were major histocompatibility (MHC) class II restricted. Limiting dilution analysis revealed SIV-specific T-helper precursor frequencies of up to 96 per 10(6) peripheral blood mononuclear cells (PBMC). Intracellular flow-cytometric analysis demonstrated the production of interleukin (IL)-2, interferon (IFN)-gamma, RANTES and macrophage inhibitory protein-1alpha (MIP-1alpha) by T lymphocytes from SIVmac239deltanef-vaccinated animals following SIV p55 stimulation. Induction of strong SIV-specific T-helper responses by live-attenuated SIV vaccines may play a role in their ability to induce protective immunity.
Asunto(s)
Vacunas contra el SIDA/inmunología , Virus de la Inmunodeficiencia de los Simios/inmunología , Linfocitos T Colaboradores-Inductores/inmunología , Animales , Recuento de Linfocito CD4 , Citometría de Flujo , Inmunidad Celular/inmunología , Inmunización/veterinaria , Interferón gamma/inmunología , Interleucina-2/inmunología , Activación de Linfocitos , Macaca mulatta , Síndrome de Inmunodeficiencia Adquirida del Simio/inmunología , Síndrome de Inmunodeficiencia Adquirida del Simio/prevención & control , Vacunas Atenuadas/inmunologíaRESUMEN
Immunization with live attenuated simian immunodeficiency virus (SIV) strains has proved to be one of the most effective strategies to induce protective immunity in the SIV/macaque model. To better understand the role that CD4(+) T helper responses may play in mediating protection in this model, we characterized SIV-specific proliferative and cytokine responses in macaques immunized with live attenuated SIV strains. Macaques chronically infected with live attenuated SIV had strong proliferative responses to SIV proteins, with stimulation indices of up to 74. The magnitude of the proliferative response to SIV Gag varied inversely with the degree of attenuation; Gag-specific but not envelope-specific responses were lower in animals infected with more highly attenuated SIV strains. SIV-specific stimulation of lymphocytes from vaccinated macaques resulted in secretion of interferon-gamma, IL-2, regulated-upon-activation, normal T cells expressed and secreted (RANTES), macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta but not IL-4 or IL-10. Intracellular flow cytometric analysis documented that, in macaques vaccinated with SIVmac239Deltanef, up to 2% of all CD4(+)T cells were specific for SIV p55. The ability of live attenuated SIV to induce a strong, sustained type 1 T helper response may play a role in the success of this vaccination approach to generate protection against challenge with wild-type SIV.
Asunto(s)
Quimiocina CCL5/biosíntesis , Proteínas Inflamatorias de Macrófagos/biosíntesis , Virus de la Inmunodeficiencia de los Simios/inmunología , Células TH1/inmunología , Vacunas Virales/inmunología , Animales , Linfocitos T CD4-Positivos/inmunología , División Celular , Células Cultivadas , Quimiocina CCL3 , Quimiocina CCL4 , Quimiocina CCL5/metabolismo , Productos del Gen gag/inmunología , Productos del Gen nef/inmunología , Interferón gamma/metabolismo , Interleucina-10/metabolismo , Interleucina-2/metabolismo , Interleucina-4/metabolismo , Líquido Intracelular/inmunología , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/inmunología , Macaca mulatta , Proteínas Inflamatorias de Macrófagos/metabolismo , Virus de la Inmunodeficiencia de los Simios/fisiología , Vacunas Atenuadas/inmunologíaRESUMEN
The entry of measles virus (MV) into human cells is mediated by the initial attachment of the viral hemagglutinin (HA) to the complement regulatory protein CD46. Two subdomains, one each within CD46 short consensus repeats (SCRs) 1 and 2, are responsible for this interaction. However, little is known about the regions within MV HA needed for a high-affinity CD46 interaction. To better define the HA-CD46 interaction, we took three approaches: chimeric domain swapping, peptide scanning, and alanine scanning mutagenesis. Chimeras of MV HA and the closely related rinderpest virus (RPV) HA were generated and tested for cell surface expression and the ability to hemadsorb CD46+ red blood cells (RBC). Exchanges with the N terminus of RPV were tolerated as MV HA could be replaced with RPV HA up to amino-acid position 154. However, both larger swaps with RPV and a small RPV HA replacement at the C terminus aborted cell-surface expression. Peptide scanning with 51 overlapping peptides derived from three MV HA regions showed one peptide, corresponding to MV HA amino acids 468-487, blocked hemagglutination of African green monkey (AGM) RBCs and inhibited MV infection of Chinese hamster ovary cells (CHO) expressing human CD46. Alanine scanning mutants mapped sites on the MV HA that were not required for trafficking to the cell surface or function in hemagglutination as well as a novel site required for CD46 interaction, amino acids 473-477.
Asunto(s)
Antígenos CD/fisiología , Hemaglutininas Virales/química , Hemaglutininas Virales/metabolismo , Virus del Sarampión/fisiología , Glicoproteínas de Membrana/fisiología , Alanina , Secuencia de Aminoácidos , Sustitución de Aminoácidos , Animales , Antígenos CD/química , Secuencia de Bases , Sitios de Unión , Células CHO , Línea Celular , Cricetinae , Cartilla de ADN , Hemaglutinación/efectos de los fármacos , Hemaglutininas Virales/genética , Humanos , Virus del Sarampión/genética , Proteína Cofactora de Membrana , Glicoproteínas de Membrana/química , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Fragmentos de Péptidos/farmacología , Reacción en Cadena de la Polimerasa , Receptores Virales/química , Receptores Virales/fisiología , TransfecciónRESUMEN
PCR amplification technology for the detection of epizootic hemorrhagic disease virus (EHDV) ribonucleic acid in cell culture and clinical specimens was developed. With oligoribonucleotide primers selected from genome segment 10 of EHDV serotype 1 (EHDV-1), which codes for two nonstructural proteins (NS3 and NS3a), the PCR-based assay resulted in a 535-bp PCR product. RNAs from North American EHDV-1 prototype, EHDV-2 prototype, and a number of EHDV field isolates, including the Central African isolates of EHDV-5 and EHDV-318 propagated in cell cultures, were detected by this PCR-based assay. The specific 535-bp PCR products were visualized onto agarose gels, and the identity of the PCR products was confirmed by chemiluminescent hybridization with a 352-bp internal probe. The sensitivity of the EHDV PCR assay was increased by chemiluminescent hybridization; by this EHDV-NS3 PCR, 10 fg of EHDV RNA was detected (equivalent to 600 viral particles). Amplification product was not detected when the PCR-based assay was applied to RNAs from North American bluetongue virus prototype serotypes 2, 10, 11, 13, and 17; total nucleic acid extracts from uninfected BHK-21 cells; or unfractionated blood from calves and deer that were EHDV seronegative and virus isolation negative. The described EHDV PCR-based assay with primers derived from segment 10 of EHDV-1 resulted in detection of EHDV RNA from blood and tissues collected from calves and deer with natural and experimental EHDV infections and provides a valuable tool to study the epidemiology of EHDV infection in susceptible ruminants.
Asunto(s)
Virus de la Enfermedad Hemorrágica Epizoótica/aislamiento & purificación , Infecciones por Reoviridae/diagnóstico , África Central , Southern Blotting/métodos , Células Cultivadas , Cartilla de ADN , Genoma Viral , Virus de la Enfermedad Hemorrágica Epizoótica/clasificación , Virus de la Enfermedad Hemorrágica Epizoótica/genética , Humanos , Hibridación in Situ , Mediciones Luminiscentes , América del Norte , Sondas de Oligonucleótidos , Reacción en Cadena de la Polimerasa/métodos , ARN Viral/análisis , Infecciones por Reoviridae/virología , Sensibilidad y Especificidad , SerotipificaciónRESUMEN
The nef gene of primate lentiviruses encodes a myristoylated protein that is important for pathogenicity and the maintenance of high virus loads. A deletion in nef leads to a significant reduction of the pathogenicity of simian immunodeficiency virus (SIV) in macaques. At the cellular and biochemical levels, Nef has been shown to down-regulate CD4 and major histocompatibility complex class I molecules and to interact with cellular protein kinases. The importance of these activities for Nef function remains uncertain. We have prepared vaccinia virus recombinants expressing different alleles of SIV nef. When grown on TK- 143 cells, recombinants constructed with the nef allele from SIVmac1A11 produced typical plaques while recombinants expressing the nef allele from SIVmac239-R1 gave rise to plaques with altered morphology. By using chimeric Nef proteins and site-directed mutagenesis, the amino acid responsible for altered plaque formation was mapped to a leucine at residue 211. In vitro phosphorylation of immunoprecipitates prepared from cells infected with the vaccinia virus recombinants resulted in labeled proteins of 62 and 90 kDa. The recombinants differed in the ability to stimulate phosphorylation, and the leucine at residue 211 was again found to be the determining amino acid. These results might help elucidate the role of nef in the pathogenesis of SIV.
Asunto(s)
ADN Recombinante/genética , Genes nef , Recombinación Genética , Virus de la Inmunodeficiencia de los Simios/genética , Virus Vaccinia/fisiología , Replicación Viral/genética , Animales , MacacaRESUMEN
Indirect enzyme linked immunosorbant assays (ELISAs) utilizing the three major structural proteins (M, N, and G(L)) of equine arteritis virus (EAV) expressed from recombinant baculoviruses were developed. A large panel of sera collected from uninfected horses, and from animals experimentally and naturally infected with EAV or vaccinated with the modified live virus vaccine against equine viral arteritis, were used to characterize the humoral immune response of horses to the three major EAV structural proteins. The data suggest that the M protein was the major target of the equine antibody response to EAV. The responses of individual animals varied and ELISAs that utilized individual EAV structural proteins were not reliable for detecting antibodies in all sera that contained neutralizing antibodies to EAV. An ELISA based on a cocktail of all three EAV structural proteins, however, was used successfully to detect antibodies in most equine sera that were positive in the standard serum neutralization assay following natural or experimental EAV infection (100% specificity, 92.3% sensitivity). In contrast, this ELISA did not reliably detect antibodies in the sera of vaccinated horses. EAV frequently causes a persistent infection in stallions and all sera from carrier stallions evaluated in this study had obvious reactivity with the N protein, whereas seropositive non-carrier stallions, mares and geldings did not respond consistently to the N protein.
Asunto(s)
Anticuerpos Antivirales/sangre , Infecciones por Arterivirus/veterinaria , Ensayo de Inmunoadsorción Enzimática/métodos , Equartevirus/inmunología , Proteínas Estructurales Virales/inmunología , Animales , Especificidad de Anticuerpos , Antígenos Virales/inmunología , Infecciones por Arterivirus/inmunología , Infecciones por Arterivirus/prevención & control , Baculoviridae/genética , Baculoviridae/metabolismo , Portador Sano/inmunología , Portador Sano/veterinaria , Equartevirus/genética , Equartevirus/aislamiento & purificación , Femenino , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/virología , Caballos , Masculino , Pruebas de Neutralización , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/metabolismo , Proteínas del Envoltorio Viral/inmunología , Proteínas de la Matriz Viral/inmunología , Proteínas Estructurales Virales/metabolismo , Vacunas Virales/inmunologíaRESUMEN
OBJECTIVE: To investigate the ability of rinderpest virus (RPV) antigens, expressed in pox virus vectors, to protect against canine distemper virus (CDV) infection in ferrets. ANIMALS: Ferrets (Mustela putorius; n = 27) with no previous exposure to CDV. PROCEDURE: Ferrets were inoculated intradermally with recombinant vaccinia viruses expressing the H gene of RPV, the F gene of RPV, the H and F genes of RPV, or fowlpox virus recombinant expressing both genes. Two ferrets were vaccinated s.c. with CDV vaccine as positive controls, and 1 group was left unvaccinated as a negative control. Blood was obtained from ferrets biweekly; antibody titer to RPV was detected by ELISA, and CDV antibody titer was measured by serum neutralization testing and ELISA. RESULTS: Partial protection was seen in all groups, with vRVFH vaccination being the most protective (60%). CONCLUSIONS AND CLINICAL RELEVANCE: A single inoculation with a vaccinia virus expressing the H and F genes of RPV was able to protect 60% of the vaccinated ferrets challenge exposed with a high dose of CDV. These results indicate the ability of RPV antigens expressed by vaccinia virus to protect ferrets against a related morbillivirus. Further, they document the safety and efficacy of a recombinant vaccinia virus vaccine for ferrets. Such vaccines may be useful given the susceptibility of ferrets to CDV and the problem of maternal antibody interfering with vaccination of young animals.
Asunto(s)
Moquillo/prevención & control , Hurones , Poxviridae/genética , Virus de la Peste Bovina/genética , Vacunación/veterinaria , Vacunas Virales , Animales , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Antígenos Virales/inmunología , Moquillo/inmunología , Ensayo de Inmunoadsorción Enzimática/veterinaria , Hurones/sangre , Hurones/inmunología , Regulación Viral de la Expresión Génica , Genes Virales , Vectores Genéticos , Hemaglutininas Virales/genética , Morbillivirus/inmunología , Infecciones por Morbillivirus/inmunología , Infecciones por Morbillivirus/prevención & control , Infecciones por Morbillivirus/veterinaria , Pruebas de Neutralización/veterinaria , Poxviridae/inmunología , Virus de la Peste Bovina/inmunología , Vacunación/métodos , Vacunas Sintéticas/genética , Vacunas Sintéticas/inmunología , Proteínas Virales de Fusión/genética , Proteínas Virales/fisiología , Vacunas Virales/genética , Vacunas Virales/inmunologíaRESUMEN
Simian immunodeficiency virus (SIV) infection of macaques is a model for human immunodeficiency virus (HIV) infection. We have previously reported the construction and characterization of an SIV vector with a deletion in the nef gene (SIV(delta nef)) and expressing gamma interferon (SIV(HyIFN)) (L. Giavedoni and T. Yilma, J. Virol. 70:2247-2251, 1996). We now show that rhesus macaques vaccinated with SIV(HyIFN) have a lower viral load than a group similarly immunized with SIV(delta nef). Viral loads remained low in the SIV(HyIFN)-vaccinated group even though SIV expressing gamma interferon could not be isolated after 6 weeks postimmunization in these animals. All immunized and two naive control macaques became infected when challenged with virulent SIV(mac251), at 25 weeks postvaccination. In contrast to the two naive controls that died by 12 and 18 weeks postchallenge, all vaccinated animals remained healthy for more than 32 weeks. In addition, postchallenge cell-associated virus load was significantly lower in SIV(HyIFN)-immunized animals than in the group vaccinated with SIV(delta nef). These findings indicate that cytokine-expressing viruses can provide a novel approach for development of safe and efficacious live attenuated vaccines for AIDS.
Asunto(s)
Interferón gamma/genética , Vacunas contra el SIDAS , Síndrome de Inmunodeficiencia Adquirida del Simio/virología , Virus de la Inmunodeficiencia de los Simios/genética , Carga Viral , Animales , Expresión Génica , Humanos , Interferón gamma/inmunología , Macaca mulatta , Virus de la Inmunodeficiencia de los Simios/inmunología , VacunaciónRESUMEN
The gene encoding the P6-like protein of Pasteurella multocida was cloned in the baculovirus expression system. Baculovirus-expressed recombinant protein was used to parenterally immunize 6-wk-old Nicholas broad-breasted white turkeys. Turkeys developed significant antibody titers to the recombinant protein as measured by enzyme-linked immunosorbent assay. Two weeks after the last immunizing injection, vaccinated turkeys were placed in contact with turkeys infected with P. multocida strain P1059, as were nonvaccinated control birds. No differences occurred in percent mortality between the two groups. We conclude that parenterally administered recombinant P6-like protein does not protect turkeys from avian cholera.
Asunto(s)
Proteínas Bacterianas/administración & dosificación , Vacunas Bacterianas/administración & dosificación , Infecciones por Pasteurella/veterinaria , Pasteurella multocida/inmunología , Enfermedades de las Aves de Corral/prevención & control , Pavos , Vacunas Sintéticas/administración & dosificación , Análisis de Varianza , Animales , Anticuerpos Antibacterianos/análisis , Anticuerpos Antibacterianos/inmunología , Proteínas Bacterianas/inmunología , Vacunas Bacterianas/inmunología , Recuento de Colonia Microbiana , Ensayo de Inmunoadsorción Enzimática/veterinaria , Femenino , Sueros Inmunes/inmunología , Infecciones por Pasteurella/inmunología , Infecciones por Pasteurella/prevención & control , Pasteurella multocida/aislamiento & purificación , Enfermedades de las Aves de Corral/inmunología , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/inmunología , Vacunas Sintéticas/inmunologíaRESUMEN
To better define the molecular epidemiology of bluetongue virus (BTV) infection, the genetic characteristics and phylogenetic relationships of the S3 genes of the five U.S. prototype strains of BTV, the commercially available serotype 10 modified live virus vaccine, and 18 field isolates of BTV serotypes 10, 11, 13, and 17 obtained in California during 1980, 1981, 1989, and 1990 were determined. With the exception of the S3 gene of the U.S. prototype strain of BTV serotype 2 (BTV 2), these viruses had an overall sequence homology of between 95 and 100%. Phylogenetic analyses segregated the prototype U.S. BTV 2 strain to a unique branch (100% bootstrap value), whereas the rest of the viruses clustered in two main monophyletic groups that were not correlated with their serotype, year of isolation, or geographical origin. The lack of consistent association between S3 gene sequence and virus serotype likely is a consequence of reassortment of BTV gene segments during natural mixed infections of vertebrate and invertebrate hosts. The prototype strain of BTV 13, which is considered an introduction to the U.S. like BTV 2, presents an S3 gene which is highly homologous to those of some isolates of BTV 10 and especially to that of the vaccine strain. This finding strongly suggests that the U.S. prototype strain of BTV 13 is a natural reassortant. The different topologies of the phylogenetic trees of the L2 and S3 genes of the various viruses indicate that these two genome segments evolve independently. We conclude that the S3 gene segment of populations of BTV in California is formed by different consensus sequences which cocirculate and which cannot be grouped by serotype.
Asunto(s)
Virus de la Lengua Azul/genética , Genes Virales , California , Filogenia , Estados UnidosRESUMEN
Some individuals in well-defined cohorts have now been infected with HIV-1 for well over a decade and yet remain clinically asymptomatic with normal CD4 counts. To determine immunologic and virologic parameters in these individuals, we examined 10 persons from the San Francisco City Clinic with firmly documented infection of 11-15 years duration who had maintained stable CD4 counts above 500 cells/microliters. Our results indicate that long-term nonprogressors are a heterogeneous group with respect to viral load and HIV-1-specific immune responses, and that progression can occur even after 15 years of stable infection. However, in a subset of persons with the lowest viral loads and persistent nonprogressive infection, we detected strong CTL responses, whereas neutralizing antibody studies revealed weak to undetectable titers against a panel of 10 primary isolates. This study demonstrates that a vigorous in vivo activated HIV-1-specific CTL response can be part of the host immune response in stable nonprogressive HIV-1 infection, and that circulating activated CTL can be detected in the setting of an extremely low viral load. These results also indicate that long-term nonprogressing HIV-1 infection does not require the presence of broadly cross-reactive neutralizing antibodies.
Asunto(s)
Anticuerpos Anti-VIH/inmunología , Infecciones por VIH/inmunología , VIH-1/inmunología , Linfocitos T Citotóxicos/inmunología , Línea Celular Transformada , Progresión de la Enfermedad , Infecciones por VIH/virología , VIH-1/crecimiento & desarrollo , Humanos , Masculino , Pruebas de Neutralización , SobrevivientesRESUMEN
We report the construction and characterization of several replication-competent simian immunodeficiency virus (SIV) vectors with a deletion in the viral nef gene (SIV(delta nef)) that express gamma interferon (IFN-gamma). The expression of the cytokine gene was controlled either by the simian virus 40 early promoter or by the SIV 5' long terminal repeat regulatory sequences, utilizing the nef gene splice signals. To enhance the expression of IFN-gamma, the two in-frame nef start codons were mutated without altering the Env amino acid sequence (SIV(HyIFN)). Plasmids containing full-length proviral genomes were used to obtain high-titer stocks of each recombinant virus in cell cultures. Expression of IFN-gamma by SIV(HyIFN) reached levels as high as 10(6) U/ml after 11 days in culture. The IFN-gamma gene was unstable and sustained deletions after serial passage of SIV(delta nef) vectors in CEM-X-174 cells. The degree of instability appears to depend on size and orientation of the insert and the expression of IFN-gamma. Only one virus, SIV(HyIFN), expressed detectable levels of IFN-gamma up to the sixth passage. Prospects for the use of IFN-gamma and other lymphokines to enhance the safety and efficacy of live attenuated vaccines are discussed.
Asunto(s)
Vectores Genéticos , Interferón gamma/genética , Virus de la Inmunodeficiencia de los Simios/genética , Secuencia de Bases , Línea Celular , Cartilla de ADN , Vectores Genéticos/genética , Humanos , Interferón gamma/biosíntesis , Datos de Secuencia Molecular , Virus de la Inmunodeficiencia de los Simios/fisiología , Replicación ViralRESUMEN
Peste des petits ruminants (PPR) is a viral disease of goats and sheep characterized by erosive stomatitis, enteritis, and pneumonia. The virus is a member of the family Paramyxoviridae and the genus Morbillivirus. The disease has high morbidity and mortality rates and has a substantial economic impact in developing countries. We have cloned and sequenced the cDNA of the nucleocapsid (N) gene of the Nigeria 75/1 strain of PPR virus (PPRV). A comparison of its nucleotide and deduced amino acid sequence with those of the N gene of the tissue culture-attenuated strain of PPRV was performed. A divergence of 8.9 and 5.0% was found at the nucleotide and amino acid level, respectively. A recombinant baculovirus that expresses the N protein in insect cells and larvae (Spodoptera frugiperda) was generated. The recombinant protein, characterized by Western blot analysis, was shown to have a molecular weight of 58 kDa and was recognized by anti-PPRV antibodies. The recombinant protein was used successfully as a coating antigen in an enzyme-linked immunosorbent assay for the serological diagnosis of PPRV.
Asunto(s)
Baculoviridae/genética , Cápside/genética , Ensayo de Inmunoadsorción Enzimática/métodos , Infecciones por Morbillivirus/diagnóstico , Virus de la Peste de los Pequeños Rumiantes/genética , Proteínas del Núcleo Viral/genética , Secuencia de Aminoácidos , Animales , Anticuerpos Antivirales/sangre , Secuencia de Bases , Cápside/biosíntesis , Cápside/química , Línea Celular , Clonación Molecular , Expresión Génica , Genes Virales/genética , Variación Genética/genética , Vectores Genéticos/genética , Datos de Secuencia Molecular , Peso Molecular , Infecciones por Morbillivirus/veterinaria , Nigeria , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/química , Análisis de Secuencia de ADN , Spodoptera , Proteínas del Núcleo Viral/biosíntesis , Proteínas del Núcleo Viral/química , Proteínas Estructurales Virales/genéticaRESUMEN
OBJECTIVE: To demonstrate that antibodies against amino acids (aa) 603-622 of the SIV gp41 transmembrane glycoprotein enhance infection of SIV in vivo. DESIGN: A synthetic peptide derived from aa 603-622 of SIVmac251 gp41 was synthesized and tested for immunogenicity in rabbits and SIV-infected rhesus macaques. Next, SIV-naive animals were immunized with either a recombinant vaccinia virus expressing the SIV gp160 envelope glycoprotein (VVrgp160) and boosted three times with aa 603-622 (group 1, four animals), wild-type vaccinia virus and boosted with aa 603-622 (group 2, two animals), or VVrgp160 followed by three doses of an irrelevant peptide (group 3, two animals). Animals were challenged with SIVmac251. RESULTS: Peptide aa 603-622 was immunogenic in rabbits. SIV-infected rhesus monkeys immunized with the peptide developed two-three log increases in antibodies to this peptide and antibodies that could enhance SIV infection in vitro. SIV-naive rhesus macaques in group 1 had higher levels of antibody to the peptide by enzyme-linked immunosorbent assay and higher levels of enhancing antibodies at the time of SIV challenge than the animals in groups 2 or 3. Following challenge with SIVmac251 the group 1 animals had detectable p27 antigen longer than animals in group 2 and 3 and died of simian AIDS before the respective animals in the two control groups (P < 0.05 by log-rank test). CONCLUSIONS: aa 603-622 of SIV gp41, like aa 579-613 of HIV gp41, can stimulate production of antibodies that enhance SIV and HIV infection in vitro. Furthermore, immunization with this peptide suppressed beneficial effects of a gp160 vaccine and appeared to enhance SIV infection in vivo.